Press Release May 19, 2022

China’s Kelun Pharma Jumps on Licensing New Cancer Drug to Merck

The Life Sciences team advised Sichuan Kelun-Biotech Biopharmaceutical Co. in its exclusive license and collaboration agreement with Merck for ex-China development rights of an experimental oncology treatment.

Kelun is a China-based company listed on the Shenzhen Stock Exchange, principally engaged in the research and development, manufacture and distribution of pharmaceutical products. 

The co-operation with Merck will help speed up Kelun’s entry into global markets and enhance the internationalization of its projects

The Goodwin team was led by Wenseng “Wendy” Pan and consisted of Kevin Guan, Nawa Lodin, Sarah Stoiber, Roger Cohen, Julie Tibbets.

For more details, read the press release and article in Endpoints.